Search the Newsreel

Revolution Medicines Reports Second Quarter 2026 Financial Results and Update on Corporate Progress

Revolution Medicines announced its Q2 2026 financial results and provided an update on corporate progress, highlighting the FDA's acceptance of daraxonrasib's New Drug Application for metastatic pancreatic cancer and the rapid implementation of an Expanded Access Program. The company also reported encouraging new combination …

Revolution Medicines stock hits all-time high of 195.48 USD By Investing.com

Revolution Medicines Inc. (RVMD) has reached an all-time stock high of $195.48, reflecting significant investor confidence with a 1-year price return of 403.93%. Despite an InvestingPro analysis suggesting the stock is overvalued, analysts from UBS, Mizuho, Wedbush, and Truist Securities have raised price targets …

Revolution Medicines (RVMD) Earnings Date and Reports 2026

Could Revolution Medicines (RVMD) Become a $20 Billion Cancer Drug Story?

Baron Capital, an investment management company, released its Q2 2026 investor letter for the "Baron Health Care Fund". A copy of the letter is available to download here. The Fund gained 11.99% during the quarter, compared with the 10.48% gain for the Russell 3000 …

Billionaire Stanley Druckenmiller Bought This Biotech Stock That Has Surged 400%. Is It Still a Buy?

Key Points Druckenmiller initiated a new stake in Revolution Medicines in Q1. The biotech stock has skyrocketed on excitement about its lead cancer candidate, daraxonrasib. Revolution Medicine's valuation makes the stock a riskier proposition now.10 stocks we like better than Revolution Medicines › Stanley …

Is Revolution Medicines (RVMD) Fully Valued Following Its FDA Filing Win?

Revolution Medicines (RVMD) has seen significant stock price appreciation following the FDA's acceptance of its New Drug Application for daraxonrasib. Despite a 137.32% year-to-date increase, Simply Wall St's analysis suggests RVMD is 8.2% undervalued, with a fair value pegged at $204.38 based on its …

Why Billionaire Stanley Druckenmiller and Wall Street Analysts Love This Biotech Stock

Key Points Druckenmiller bought 316,000 shares of Revolution Medicines in the first quarter. The company doesn't generate revenue yet and lost $453 million in the first quarter. Revolution uses RAS proteins to treat aggressive cancers.10 stocks we like better than Revolution Medicines › Shares …

Price to earnings forward of Revolution Medicines, Inc. – BOATS:RVMDW

The article focuses on the "Price to earnings forward" for Revolution Medicines, Inc. (RVMDW), listed on the Blue Ocean Alternative Trade System (BOATS). It presents financial information related to RVMDW, including market status and data provided by ICE Data Services and FactSet. The page …

FDA Priority Review For Daraxonrasib Might Change The Case For Investing In Revolution Medicines (RVMD)

Revolution Medicines (RVMD) has received FDA priority review for its New Drug Application for daraxonrasib, an oral RAS(ON) multi-selective inhibitor, for metastatic pancreatic cancer. This decision, backed by positive Phase 3 data, is a significant catalyst for the company, potentially reshaping its investment narrative …

Sandra Heller Joins Revolution Medicines as Vice President & General Manager, Canada

Revolution Medicines has appointed Sandra Heller as Vice President & General Manager for Canada, enhancing its commercial leadership in oncology. Heller brings over 25 years of experience from companies like Astellas Pharma Canada, Seagen, Gilead Sciences, and Roche, and will lead Canadian operations, commercial …

Enterprise value to EBIT forward of Revolution Medicines, Inc. – NASDAQ:RVMDW

This article focuses on the enterprise value to EBIT forward of Revolution Medicines, Inc. (NASDAQ: RVMDW). The content primarily serves as a financial data point or a placeholder within the TradingView platform for the company's financial metrics.

Revolution Medicines Number of Employees 2026 | Employee Count & Headcount Data

Revolution Medicines, Inc. (NASDAQ: RVMD) had approximately 1,025 employees worldwide as of March 2026, marking an 83.5% growth since 2023. The company is actively hiring, with 384 active job postings in 2026, and its workforce is primarily concentrated in the United States. Employee sentiment …

Revolution Medicines (NASDAQ:RVMD) Flashes Strong Technical Breakout Setup

Revolution Medicines (NASDAQ:RVMD) is showing a strong technical breakout setup, scoring 9 out of 10 on both ChartMill's Technical Rating and Setup Quality Rating. This indicates a sustained positive trend with the stock trading well above its moving averages and near its 52-week high, …

BlackRock (NYSE: BLK) reports 5.7% ownership in Revolution Medicines (RVMD)

BlackRock, Inc. has disclosed a 5.7% beneficial ownership stake in Revolution Medicines (RVMD), amounting to 12,201,395 common shares. This ownership gives BlackRock sole voting power over 11,508,777 shares and sole dispositive power over all 12,201,395 shares. The filing, a Schedule 13G, indicates that these …

Meet the Stock That's Obliterating Eli Lilly, Johnson & Johnson, and AbbVie Right Now

Key Points Revolution Medicines has a promising cancer drug in development. Even with this medicine's prospects, the stock's valuation looks too frothy. 10 stocks we like better than Revolution Medicines › Shares of Revolution Medicines(NASDAQ: RVMD), a clinical-stage drugmaker, have gained 132% this year, …

Revolution Medicines to webcast Q2 update Aug. 5 at 4:30 p.m.

Revolution Medicines (Nasdaq: RVMD) will report its second quarter 2026 financial results on Wednesday, August 5, 2026, after market close. Senior management will host a live webcast at 4:30 p.m. ET (1:30 p.m. PT) to discuss the results and provide a corporate update. A …

Revolution Medicines to Report Financial Results for Second Quarter 2026 After Market Close on August 5, 2026

Revolution Medicines, Inc. announced it will report its second-quarter 2026 financial results on August 5, 2026, after market close. A webcast will follow at 4:30 p.m. ET to discuss the results and corporate progress. The company specializes in developing targeted therapies for RAS-addicted cancers.

Revolution Medicines (RVMD) Expected to Announce Earnings on Wednesday

Revolution Medicines, Inc. Revenue Breakdown – FWB:42Z

This article provides a revenue breakdown for Revolution Medicines, Inc. (FWB:42Z) listed on the Frankfurt Stock Exchange. It highlights the availability of financial data, statements, statistics, dividends, and earnings reports, which are crucial for detailed financial analysis of the company's performance. The article also …

Revolution Medicines Inc (RVMD) Cash Flow

This article provides a detailed quarterly and annual cash flow statement for Revolution Medicines Inc (RVMD), covering operating, investing, and financing activities. It presents historical data from FY2018Q4 to FY2026Q1, including net income, capital expenditures, and changes in working capital. The piece also includes …

Revolution Medicines stock hits all-time high at $193.83

Revolution Medicines Inc. stock has reached an all-time high of $193.83, with a market capitalization of $41.06 billion and a 407.86% increase over the past year. Despite this surge, InvestingPro data suggests the stock may be overvalued and the company is not expected to …

Can Revolution Medicines (RVMD) Get Any Less Expensive After Its Run?

Revolution Medicines (RVMD) has seen significant share price appreciation, returning 6.4x over the past three years and 399.2% in the last year, largely due to positive daraxonrasib news. Despite this strong performance and prospects from its RAS oncology pipeline, the stock appears expensive with …

Revolution Medicines Stock Surges 400% in a Year, But Is the Rally Running on Fumes?

Revolution Medicines (RVMD) stock has soared 400% in the past year, driven by FDA acceptance of its daraxonrasib NDA for pancreatic cancer and a strong pipeline. However, its valuation metrics, particularly a P/B ratio of 26.8x, suggest it might be overvalued, as it passes …

Revolution Medicines (RVMD) Wins FDA Review Milestone For Daraxonrasib In Pancreatic Cancer

Revolution Medicines (RVMD) announced that the FDA has accepted its New Drug Application for daraxonrasib for pancreatic cancer and has granted it National Priority Voucher program status, with regulatory reviews also beginning in Europe. This marks significant progress for the company's RAS(ON) inhibitor, addressing …

Revolution Medicines (RVMD) Stock Looks Fully Priced With Strong Returns But Weak Value Checks

Make better investment decisions with Simply Wall St's easy, visual tools that give you a competitive edge. Revolution Medicines stock has delivered very strong returns in recent years, yet its current valuation checks lean expensive. This sets up a clear tension between the share …

Can Revolution Medicines (RVMD) Justify Its Valuation On Daraxonrasib Survival Data?

Make better investment decisions with Simply Wall St's easy, visual tools that give you a competitive edge. Revolution Medicines (RVMD) drew fresh attention after reporting that its experimental treatment daraxonrasib nearly doubled survival for pancreatic cancer patients who had exhausted other options, raising questions …

Big pharma’s patent cliff meets a new biotech Cold War: We need to outrun China, not outlaw it

Patrick Swayze, Alex Trebek, and Ruth Bader Ginsburg all died of pancreatic cancer. They were wealthy enough to afford any treatment that existed. But there simply wasn't a drug available — at any price — that could save their lives. This is the cruelest …

Revolution Medicines (RVMD) Is Up 5.3% After FDA Priority Review For Pancreatic Cancer Drug Approval Bid

Revolution Medicines (RVMD) saw a 5.3% increase after the FDA granted priority review to its New Drug Application for daraxonrasib, a pancreatic cancer drug. The review is supported by positive Phase 3 data showing improved survival rates for previously treated metastatic pancreatic ductal adenocarcinoma. …

FDA Accepts RVMD's Filing for Daraxonrasib in Pancreatic Cancer

The FDA has accepted Revolution Medicines' regulatory filing for daraxonrasib, a drug targeting metastatic pancreatic ductal adenocarcinoma, under a program designed for accelerated review of therapies for life-threatening diseases. Clinical trial data shows daraxonrasib significantly reduced the risk of death by 60% and nearly …

Revolution Medicines' NDA For Daraxonrasib Accepted By FDA For Metastatic Pancreatic Cancer

(RTTNews) - Revolution Medicines, Inc. (RVMD) announced that the U.S. FDA has accepted for review its New Drug Application (NDA) for daraxonrasib, an oral RAS(ON) multi-selective inhibitor, for patients with metastatic pancreatic ductal adenocarcinoma. Metastatic pancreatic ductal adenocarcinoma (PDAC) is one of the most …

Revolution Medicines' Application for Pancreatic Cancer Treatment Accepted by FDA

Revolution Medicines announced the FDA has accepted its Investigational New Drug (IND) application for RMC-9807, an oral RAS(ON) inhibitor, for the treatment of pancreatic cancer. This decision allows the company to initiate a Phase 1/1b clinical trial to evaluate the drug's safety and efficacy …

Revolution Medicines (RVMD) Sees FDA Acceptance for Daraxonrasib Review

Revolution Medicines Inc. (RVMD) received FDA acceptance for its new drug application for daraxonrasib, a targeted treatment for metastatic pancreatic ductal adenocarcinoma. Despite this positive development, the company holds a low GF Score™ of 30, and insiders have sold $25.5 million worth of shares …

FDA accepts review of Revolution Medicines' daraxonrasib for metastatic pancreatic cancer treatment

The FDA has accepted Revolution Medicines' New Drug Application for daraxonrasib, a targeted therapy for metastatic pancreatic ductal adenocarcinoma. This decision follows positive Phase 3 trial results that demonstrated improved survival and quality of life for patients. Daraxonrasib targets RAS mutations and has received …

Revolution Medicines’ New Drug Application for Daraxonrasib

Revolution Medicines, Inc. announced that the U.S. FDA accepted its New Drug Application (NDA) for daraxonrasib, an oral RAS(ON) multi-selective inhibitor, for previously treated metastatic pancreatic ductal adenocarcinoma. The NDA is based on positive Phase 3 RASolute 302 trial results showing improved overall and …

Oral Investigational Medicine for Pancreatic Cancer Is Accepted for FDA Review

Revolution Medicines (Nasdaq: RVMD) announced that the U.S. FDA has accepted for review its New Drug Application (NDA) for daraxonrasib, an oral RAS(ON) multi-selective inhibitor, for previously treated metastatic pancreatic ductal adenocarcinoma (PDAC). The NDA is supported by the global Phase 3 RASolute 302 …

Is Revolution Medicines (RVMD) A Bargain As Daraxonrasib Trial Results Lift Its Outlook?

Revolution Medicines (RVMD) is under scrutiny after positive Phase III results for Daraxonrasib and new FDA designations, boosting its stock price significantly. While Simply Wall St's narrative suggests the stock is 39.2% overvalued at $186.16 compared to a fair value of $133.70, their DCF …